Authors: Gary L. Murray.
This commentary is inspired by the 12 year study of 133 type II diabetics (DM) in whom sudden cardiac death(SCD) risk was identified with one autonomic screening and addressed , reducing SCD 43% (p = 0.0076) [1], as well as studies identifying/treating autonomic markers of major adverse cardiac events( MACE) in congestive heart failure(CHF), HTN, and coronary disease(CAD)[2-6] resulting in improved outcomes. Since oxidative stress, and secondary dysautonomia, is a common thread of all major cardiac disease, and there is preventative/corrective therapy, a new paradigm of screening/treating oxidative-stress cardiac dysautonomia as a major common final pathway to MACE should be considered.
View/Download pdf